

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 45/06, 31/57, 31/58, 31/135, 31/35, 31/245, 31/09, 31/38, 31/195, 31/47, 31/445, 31/55, 31/44, 31/615, 31/415	A1	(11) International Publication Number: WO 98/48839 (43) International Publication Date: 5 November 1998 (05.11.98)
--	-----------	--

(21) International Application Number: PCT/US98/06483
(22) International Filing Date: 2 April 1998 (02.04.98)

(30) Priority Data:
60/044,306 30 April 1997 (30.04.97) US

(71) Applicant (for all designated States except US):
WARNER-LAMBERT COMPANY [US/US]; 201
Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SEGAL, Catherine, A.
[US/US]; 60 Shawnee Avenue, Rockaway, NJ 07866 (US).

(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201
Tabor Road, Morris Plains, NJ 07950 (US) et al.

(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ,
EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT,
LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL,
TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM,
KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: TOPICAL NASAL ANTIINFLAMMATORY COMPOSITIONS

(57) Abstract

The present invention provides topically applicable nasal compositions comprising a therapeutically effective amount of an antiinflammatory agent and a therapeutically effective amount of at least one agent selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an antihistamine, an antiallergic agent, an anticholinergic agent, an anesthetic and a mucolytic agent. The present compositions are useful as nasal sprays and nose drops for the treatment of nasal and sinus conditions.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TOPICAL NASAL ANTIINFLAMMATORY COMPOSITIONS

SPECIFICATION

BACKGROUND OF THE INVENTION

5 Topical nasal antiinflammatory preparations are known in the art for
the treatment of inflammatory conditions of the nasal mucous membranes, and in
particular for relief of the symptoms of nasal and sinus conditions such as rhinitis.
However, nasal and sinus conditions may be characterized by diverse symptoms
requiring treatment with multiple therapeutic agents. For example, allergic rhinitis
10 may be characterized by rhinorrhea, nasal itching, sneezing, congestion and postnasal
drip and treatment may require antihistamines, decongestants, antiallergics and
anesthetics in addition to antiinflammatories.

15 The use of multiple topical nasal preparations to administer multiple
therapeutic agents suffers from significant disadvantages. The volume of liquid that
can effectively be applied nasally is limited by the surface area of the nostril and the
bioadhesiveness of the liquid. In addition, a sufficient contact time between topical
preparations and the surface area of the nostril is required to assure adequate dosing
of a therapeutic agent. Further, spray formulations require a threshold surface
20 tension to form droplets. Accordingly, the delivery volume per actuation is limited to
the volume that will be retained in the nostril without premature drainage. Thus
multiple topical nasal preparations cannot be effectively administered simultaneously.

Another disadvantage of the administration of multiple topical nasal preparations is patient inconvenience. Patient compliance may be compromised by the inconvenience of applying multiple spray products or nose drops. Patients complain when excess spray drains into their throats where it can be tasted, resulting in a need for flavor masking of bitter medicaments.

Accordingly, a need exists for a convenient means of nasal administration of multiple therapeutic agents.

SUMMARY OF THE INVENTION

The present invention provides topically applicable nasal compositions comprising a therapeutically effective amount of a topical antiinflammatory agent and a therapeutically effective amount of at least one agent suitable for topical nasal administration and selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, an anticholinergic agent, a leukotriene inhibitor, an antihistamine, an antiallergic agent, an anesthetic, and a mucolytic agent.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides topically applicable nasal compositions comprising a topical antiinflammatory agent and at least one additional therapeutic agent. The present compositions are useful for the treatment of nasal and sinus conditions, for example allergic rhinitis or the common cold.

The topical antiinflammatory agents in the compositions of the present invention are corticosteroids known in the art to suppress inflammation. In a preferred embodiment the topical antiinflammatory agent is beclomethasone dipropionate, budesonide, dexamethasone, mometasone furoate, fluticasone propionate or triamcinolone acetonide. The compositions contain a therapeutically effective amount of the selected antiinflammatory agent. Those of ordinary skill in the art can determine an amount that is therapeutically effective for the suppression of inflammation. The precise amount will depend upon the method of administration and the age, weight and condition of the subject to be treated. Generally the

antiinflammatory agents are utilized in dosages known in the art to be therapeutically effective upon nasal administration.

5 The compositions of the invention further comprise at least one additional therapeutic agent, and thus allow the convenient administration of an antiinflammatory agent and at least one additional therapeutic agent in a single topical nasal composition. The additional therapeutical agent is suitable for topical nasal administration and is selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an anticholinergic agent, an antihistamine, an antiallergic agent, a local anesthetic and a mucolytic agent. The use
10 of an additional therapeutic agent in combination with an antiinflammatory agent provides additive and synergistic effects in the treatment of nasal and sinus conditions.

Vasoconstrictors suitable for topical nasal administration in the compositions of the present invention are oxymetazoline naphazoline,
15 xylometazoline, and phenylephrine. Leukotriene inhibitors include zafirlukast, a selective, competitive receptor antagonist of the three leukotrienes C4, D4, and E4; pranlukast, a selective, competitive receptor antagonist of D4; and zileuton, a leukotriene inhibitor. A neuramidinase inhibitor includes zanamivir (GG-167). Suitable antihistamines are diphenhydramine, chlorpheniramine, cetirizine terfenadine,
20 fenofexadine, astemizole norastemizole, azelastine, and azatidine. Antiallergic agents include cromolyn sodium and nedocromil levocabastine. An anticholinergic agent useful in the compositions of the present invention is ipratropium bromide. Local topical anesthetics include dyclonine, pramoxine, and benzocaine. Mucolytic agents suitable for topical nasal administration are acetylcysteine, guaifenisin and
25 mucocysteine. The therapeutically effect amount of foregoing agents can be determined by the ordinarily skilled artisan with regard to the known use of these agents in the art and taking into account the method of administration and the age, weight and condition of the subject to be treated.

30 The compositions of the present invention are formulated as aqueous solutions comprising an antiinflammatory agent and at least one additional therapeutic agent and further comprising a pharmaceutically acceptable nasal carrier.

The formulation of pharmaceutical compositions is generally known in the art and reference can be conveniently made to standard text such as Remington's Pharmaceutical Sciences, 1985, 17th ed., Mack Publishing Co., Easton, Pennsylvania.

Preferred nasal formulations are nose drops or nasal sprays containing
5 a water buffered aqueous solution as a carrier. The compositions are preferably isotonic. Isotonic agents such as a sugars and sodium chloride are known in the art and may be included in the subject compositions.

The compositions of the present invention may also contain a
humectant to increase viscosity and effect moisturization and ciliary vitality. Suitable
10 humectants include glycerin, polyethylene glycol, propylene glycol and mixtures thereof.

Additional agents including pharmaceutically acceptable preservatives, stabilizers, flavoring agents, and pH adjusters are known in the art and may be included in the present compositions.

Another embodiment of the present invention provides preservative-
15 free compositions comprising an anti-inflammatory agent and at least one additional therapeutic agent. Preservative-free compositions are preferred due to reduced sensitivity and increased patient acceptance. These can be prepared in unit dose or in systems which prevent contamination of the reservoir of solution.

The compositions of the present invention can be conveniently
20 administered nasally to a human subject in dosage unit form to elicit the desired therapeutic effect of the antiinflammatory agent and the additional therapeutic agents described above. The compositions may be administered in the form of a nasal spray or nose drops. Nasal sprays may be provided as squeeze bottles or metered dose
25 manual nasal spray pumps designed to deliver the desired dose in one or two sprays, for example. The composition may also be administered as aerosol spray formulations, for example as metered dose pressurized aerosols containing propellants such as halogenated hydrocarbons.

WHAT IS CLAIMED IS:

1. A topically applicable nasal composition comprising a therapeutically effective amount of a topical antiinflammatory agent and a therapeutically effective amount of at least one agent suitable for topical nasal administration and selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an antihistamine, an antiallergic agent, a cholinergic agent, an anesthetic and a mucolytic agent.
2. The composition of Claim 1 wherein said topical antiinflammatory agent is selected from the group consisting of beclomethasone dipropionate, budesonide, dexamethasone, mometasone furoate, fluticasone propionate and triamcinolone acetonide.
3. The composition of Claim 1 wherein said vasoconstrictor is selected from the group consisting of oxymetazoline, naphazoline, xylometazoline, and phenylephrine.
4. The composition of Claim 1 wherein said antihistamine is selected from the group consisting of diphenhydramine, chlorpheniramine, terfenadine, azelastine, norastemizole, fexofenadine, cetirazine, astemizole and azatidine.
5. The composition of Claim 1 wherein said antiallergic agent is selected from the group consisting of cromolyn sodium, levocabastine, and nedocromil.
6. The composition of Claim 1 wherein said anticholinergic agent is ipratropium.
7. The composition of Claim 1 wherein said topical anesthetic is selected from the group consisting of dyclonine, pramosine, and benzocaine.

8. The composition of Claim 1 wherein said mucolytic agent is selected from the group consisting of acetylcysteine, guaifenesin and mucocysteine.

9. The composition of Claim 1 wherein said leukotriene inhibitor is selected from the group consisting of zafirlukast, pranlukah, and zileuton.

10. The composition of Claim 1 wherein said neuramidinase inhibitor is zanamivir.

11. A topically applicable nasal composition comprising a therapeutically effective amount of a topical antiinflammatory agent selected from the group consisting of beclomethasone dipropionate, budesonide, dexamethasone, mometasone furoate, fluticasone propionate and triamcinolone acetonide and a therapeutically effective amount of at least one agent selected from the group consisting of oxymetazoline, phenylephrine, diphenhydramine, chlorpheniramine, terfenadine, astemizole, azatidine, cromolyn sodium, nedocromil, ipratropium bromide, dyclonine, benzocaine, acetylcysteine, guaifenesin and mucocysteine.

12. The composition of Claim 1 or 11 further comprising at least one humectant.

13. The composition of Claim 12 wherein said humectant is selected from the group consisting of glycerin, polyethylene glycol and propylene glycol.

14. The composition of Claim 1 or 11 comprising a pharmaceutically acceptable carrier.

15. The composition of Claim 1 or 11 formulated for application as a nasal spray.

16. The composition of Claim 1 or 11 formulated for application as nose drops.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06483

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K45/06 A61K31/57 A61K31/58 A61K31/135 A61K31/35
A61K31/245 A61K31/09 A61K31/38 A61K31/195 A61K31/47
A61K31/445 A61K31/55 A61K31/44 A61K31/615 A61K31/415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 01337 A (MCNEIL-PPC, INC.) 16 January 1997 see abstract see page 2, line 8 - line 18 see page 8, line 2 - line 24 ---	1,2,4, 11-16
X	WO 97 01341 A (MCNEIL-PPC, INC.) 16 January 1997 see page 2, line 5 - line 14 see page 8, line 2 - line 19 ---	1,2,5, 11-16
X	WO 93 09764 A (CENTER FOR INNOVATIVE TECHNOLOGY) 27 May 1993 see page 6, line 10 - line 14 see page 6, line 30 see page 22, line 23 - line 33 see page 26, line 23 - line 25 see claims 1,2,4-8,13-23 ---	1,3,4,6, 14-16
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

11 June 1998

Date of mailing of the international search report

22/06/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alvarez Alvarez, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06483

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Week 8733 Derwent Publications Ltd., London, GB; AN 87-230755 XP002067758 & JP 62 153 227 A (SEKISUI CHEM. IND. CO. LTD.) , 8 July 1987 see abstract</p>	1,2,4,7
X	<p>WO 95 07103 A (THE PROCTER & GAMBLE COMPANY) 16 March 1995 see abstract see page 4, line 7 - line 13 see page 5, line 11 - line 31 see page 7, line 16 - line 18 see page 7, line 20 see examples 1-5</p>	1,3,4,8, 12-14
A		7
X	<p>US 3 482 015 A (FREDERICK W. BOLLINGER ET AL.) 2 December 1969 see the whole document</p>	1-3,11, 12,14,15
X	<p>WO 85 04589 A (SUNSHINE ET AL.) 24 October 1985 see claims 1,14,15,17-19</p>	1,3,4,8, 14
X	<p>WO 97 09067 A (BAYER AG. ET AL) 13 March 1997 see claims 1,5</p>	1,2
A		9
X	<p>US 4 053 628 A (NEIL ARTHUR STEVENSON ET AL.) 11 October 1977 see column 3, line 10 - line 18 see claim 2</p>	1,5
X,P	<p>EP 0 780 127 A (THE PROCTER & GAMBLE COMPANY) 25 June 1997 see page 2, line 35 - line 46 see page 3, line 14 - line 30 see page 4, line 5 - line 32 see page 4, line 38 - line 40 see page 5, line 7 - line 9 see claims 1-6</p>	1-5,8, 11-16

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US.98/06483

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9701337 A	16-01-1997	AU 6392496 A	30-01-1997
WO 9701341 A	16-01-1997	AU 6290396 A	30-01-1997
WO 9309764 A	27-05-1993	US 5240694 A	31-08-1993
		CA 2122719 A	27-05-1993
		EP 0661967 A	12-07-1995
		JP 8508007 T	27-08-1996
		US 5422097 A	06-06-1995
		US 5492689 A	20-02-1996
WO 9507103 A	16-03-1995	AU 7604094 A	27-03-1995
		BR 9407414 A	12-11-1996
		CA 2170488 A	16-03-1995
		CN 1130354 A	04-09-1996
		EP 0719156 A	03-07-1996
		JP 9502201 T	04-03-1997
US 3482015 A	02-12-1969	DE 1617610 A	20-04-1972
		FR 1481087 A	09-08-1967
		GB 1089043 A	
		NL 6601472 A	09-08-1966
WO 8504589 A	24-10-1985	US 4552899 A	12-11-1985
		AU 2029195 A	03-08-1995
		AU 589554 B	19-10-1989
		AU 4120085 A	01-11-1985
		CA 1258430 A	15-08-1989
		DE 3585495 A	09-04-1992
		EP 0180597 A	14-05-1986
		JP 61501913 T	04-09-1986
		US 4749697 A	07-06-1988
		US 4839354 A	13-06-1989
		US 4749722 A	07-06-1988
		US 4749711 A	07-06-1988
		US 4749723 A	07-06-1988
		US 4749720 A	07-06-1988
		US 4749721 A	07-06-1988
		US 4783465 A	08-11-1988
		US 4920149 A	24-04-1990

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06483

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8504589 A		US 4840962 A	20-06-1989
		US 4871733 A	03-10-1989
		US 5025019 A	18-06-1991
		US 4619934 A	28-10-1986
		US 4738966 A	19-04-1988
WO 9709067 A	13-03-1997	DE 19532714 A	06-03-1997
		AU 6984496 A	27-03-1997
US 4053628 A	11-10-1977	GB 1473318 A	11-05-1977
		GB 1399834 A	02-07-1975
		US 3975536 A	17-08-1976
		AU 465305 B	25-09-1975
		AU 4208072 A	15-11-1973
		BE 782981 A	03-11-1972
		CA 1000201 A	23-11-1976
		CY 955 A	22-12-1978
		DE 2223237 A	14-12-1972
		DE 2266025 A	07-03-1985
		DK 131324 B	30-06-1975
		FR 2139872 A	12-01-1973
		HK 69276 A	12-11-1976
		NL 7206251 A, B	14-11-1972
		SE 396011 B	05-09-1977
		ZA 7202823 A	28-03-1973
		DE 2425281 A	19-12-1974
		FR 2230358 A	20-12-1974
		JP 1160498 C	10-08-1983
		JP 50040720 A	14-04-1975
		JP 57056448 B	30-11-1982
EP 780127 A	25-06-1997	NONE	

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)